ClinicalTrials.gg
Active, not recruitingNCT06417775UBRO MMUpdated Aug 14, 2026

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

A Phase 3 interventional study of Ubrogepant and Placebo for Ubrogepant in Migraine, sponsored by AbbVie. Active, not recruiting at 106 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Planned enrollment
8th of 14
496 · median 507
Started
2024
the only one that year
Phase 3
7 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
6 of 14
AbbVie

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 8th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 3, and was the 14th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed.

Ubrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico.

Participants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks).

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine
  • Menstrual Migraine
  • Ubrogepant
  • UBRELVY
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura.
  • Have experienced migraine attacks in at least 2 of 3 perimenstrual periods (PMPs) during the screening period.
  • Collection of daily eDiary data for 3 perimenstrual periods during the up to 16-week screening period to confirm a menstrual migraine (MM) diagnosis.
  • Have regular menstrual cycles of between 21-35 days in length.
  • Less than 15 headache days per month.
  • At least 70% compliance completing screening period and at least 3 out of 5 days of ediary data in each of 3 screening PMP.

Exclusion criteria

Exclusion Criteria:

  • History of migraine with brainstem aura, hemiplegic migraine, or retinal migraine.
  • history of cardiovascular or cerebrovascular disease per the investigator's opinion.
  • Clinically significant abnormalities in the physical examination as determined by the investigator.
  • Clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, gynecological, or neurologic disease per the investigator's opinion.
  • Acute headache medication overuse.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
496 participants (estimated)

Study arms

  • Experimental
    Double-Blind Period: Ubrogepant

    Participants will receive ubrogepant during the double-blind period.

    Drug: Ubrogepant

  • Experimental
    Double-Blind Period: Placebo for Ubrogepant

    Participants will receive placebo during the double-blind period.

    Drug: Placebo for Ubrogepant

  • Experimental
    Open-Label Extension Period: Ubrogepant

    Eligible participants from Double-Blind period may continue to receive ubrogepant during the open-label extension period.

    Drug: Ubrogepant

Interventions

  • Oral Tablets

    Also known as: UBRELVY

  • DrugPlacebo for Ubrogepant

    Oral Tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    A migraine day is defined as any calendar day on which a headache occurs which meets criteria listed in the protocol as per eDiary.

    Time frame: Up to approximately 16 Weeks

  2. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 68 Weeks

Secondary outcomes

  1. Change From Baseline in Number of Headache Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication was used after the start of the headache, in which case no minimum duration will be specified.

    Time frame: Up to approximately 16 Weeks

  2. Change From Baseline in Number of Moderate or Severe Headache Days During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    A headache day is defined as any calendar day on which headache pain lasting 2 hours or longer occurs unless an acute headache medication was used after the start of the headache, in which case no minimum duration will be specified.

    Time frame: Up to approximately 16 Weeks

  3. Change From Baseline in Number of Migraine Days With Moderate or Severe Headache During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    A migraine day is defined as any calendar day on which a headache occurs which meets criteria listed in the protocol as per eDiary.

    Time frame: Up to approximately 16 Weeks

  4. Percentage of Participants With No Disability/ Mild Impairment for most (>= 65%) of PMP Days

    Functional Disability Scale (FDS) is a single item used to measure the participant's level of functional disability. Participants will be asked to rate the performance of daily activities in the past 24 hours using 4 response options ranging from "No disability, able to function normally" to "Severely impaired, cannot do all or most things, bed rest may be necessary."

    Time frame: Up to approximately 16 Weeks

  5. Change From Baseline in Acute Medication Use Days During the Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) for the acute treatment of migraine.

    Time frame: Up to approximately 16 Weeks

  6. Percentage of Participants Achieving >= 50% Reduction in Number of Migraine Days During the Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period

    A migraine day is defined as any calendar day on which a headache occurs which meets criteria listed in the protocol as per eDiary.

    Time frame: Up to approximately 16 Weeks

  7. Percentage of Participants Achieving "Not at all limited" or "A little limited" Daily Activity Level for Most (>= 65%) of PMP Days

    Activity Level is a single-item used to assess overall limitations with performing daily activities over 24 hours with a 5-level response ranging from "Not at all limited" to "Unable to do daily activities."

    Time frame: Up to approximately 16 Weeks

07

Study locations

106 sites

Showing the first 100 of 106 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Nov 2027, 38 months after the start.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's planned 38 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2024
First posted
May 16, 2024
StartActual
Sep 10, 2024
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06417775
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 16, 2024
Start date
Sep 10, 2024
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion